目的：探讨帕利哌酮缓释片与利培酮治疗精神分裂症的临床疗效和安全性。方法将150例精神分裂患者随机分为两组，每组75例，分别口服帕利哌酮缓释片和利培酮治疗，观察8周。治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果研究组治疗第2周末起，对照组治疗第4周末起，阳性与阴性症状量表总分及各因子分均较治疗前显著下降（ P＜0.05或0.01）；研究组治疗第2周末阳性与阴性症状量表总分及阳性症状、一般病理因子分较对照组下降更显著（χ2＝0.68，P＜0.05）；治疗8周末研究组总有效率为78.7％，对照组为73.3％，两组比较差异无显著性（ P＞0.05）。研究组不良反应发生率为26.7％，对照组为60.0％，研究组不良反应发生率显著低于对照组（χ2＝7.39，P＜0.01）。结论帕利哌酮缓释片与利培酮治疗精神分裂症疗效显著，总体疗效相当，但帕利哌酮缓释片起效更快，安全性高，更有利于提高患者的治疗依从性。%Objective To explore the efficacy and safety of paliperidone extended‐release tablets and ris‐peridone in the treatment of schizophrenia .Methods A total of 150 schizophrenics were randomly as‐signed to two groups of 75 ones each ,they took orally paliperidone extended‐release tablets or risperidone for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results The total and each factor score lowered more significantly since the end of the 2nd week in research group and since the 4th in control group compared with pretreatment ( P<0.05 or 0.01);at the end of the 2nd week the total ,negative symptom and general pathology score lowered more significantly in research than control group (χ2 = 0.68 ,P< 0.05);at the end of the 8th week the total effective rate was respectively 78.7% in research and 73.3% in control group ,which showed no significant difference (P>0.05) .The incidence of adverse reactions was significantly lower in research than in control group (26.7% vs . 60.0% ,χ2 = 7.39 , P< 0.01) .Conclusion Both paliperidone extended‐release tablets and risperidone have an evident effect in the treatment of schizophrenia ,their total efficacies are equivalent ,but the former takes effect more rapidly ,has higher safety ,and is more favourable to the improvement of patients’ treat‐ment compliance .
展开▼
